VelaVigo's Nectin-4/TROP2 Bispecific ADC VBC103 Receives IND Approvals in Both China and the U.S.

Medical News

November 26,CDE Official Website Announcement: VBC103, developed by Orange Sail Pharmaceuticals, has been granted tacit approval for clinical trials. The proposed indication is for advanced malignant solid tumors (including but not limited to urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, ovarian cancer, and cervical cancer). VBC103 is a bispecific antibody-drug conjugate (ADC) targeting Nectin-4 and TROP2, developed by Orange Sail Pharmaceuticals.

November 27,IASO Bio Announces Its Self-Developed Fully Human TargetedBCMA CAR-T Cell Therapy Product Fucaso® (Equecabtagene Autoleucel Injection) Approved by Hong Kong Department of Health for Marketing in China, for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) Who Have Progressed After at Least Three Prior Lines of Therapy.

November 27,CDE Official Website Announcement: IND Application for Visirna's VSA012 Injection Approved for Treatment of Complement-Related Nephropathies, Including but Not Limited to Lupus Nephritis, IgA Nephropathy, C3 Glomerulopathy, Immune Complex-Mediated Membranoproliferative Glomerulonephritis, and Atypical Hemolytic Uremic Syndrome (aHUS). Previously, VSA012 Injection Was Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).

On November 26, Walvax Biotechnology Co., Ltd. announced that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary, Yuxi Walvax Biotechnology Co., Ltd., had recently received the "Biological Product Marketing License" issued by the Egyptian Drug Authority (EDA). This marks that the vaccine has obtained marketing approval in Egypt.

Investment and Financing Pharmaceutical Affairs

Recently, Weike Biotechnology (Shanghai) Co., Ltd. announced the completion of nearly 100 million yuanSeries A Financing. This round of financing was led by Shenzhen Capital Group, with Xichuang Investment following. Fenghe Capital served as the exclusive financial advisor. This round of financing will help Vico Biotechnology accelerate the construction of CGT US safety evaluation testing laboratories, CGT safety evaluation services, CGT clinical services, and the overseas business expansion of biobreeding services.

On November 25, researchers from Cold Spring Harbor Laboratory published a research paper titled "Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness" in the Nature Aging, a subsidiary journal of Nature. The study developed a CAR-T cell therapy targeting uPAR and demonstrated its ability to reverse and prevent aging-associated defects in intestinal regeneration and health.

[1]Eskiocak, O., Gewolb, J., Shah, V. et al. Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness. Nat Aging (2025). https://doi.org/10.1038/s43587-025-01022-w